Join our daily newsletter At The Bell to receive exclusive market insights
- Medicinal cannabis company Zelira Therapeutics (ZLD) is set to distribute its HOPE products in Washington, D.C. through its partnership with Alternative Solutions
- The HOPE products consist of two pharmaceutical-grade proprietary medicinal cannabis formulations developed to target Autism Spectrum Disorder (ASD) as a disease indication
- The distribution of HOPE through Washington, D.C.’s National Holistic Healing Centre will see the products be accessible to patients registered across all states in the U.S., where legal purchases of medical cannabis products can be made through approved dispensaries
- Zelira says it remains focused on further expanding the distribution of HOPE through licensing agreements in each approved market across the U.S.
- Zelira Therapeutics shares are trading steady at 5.3 cents
Medicinal cannabis company Zelira Therapeutics (ZLD) is set to distribute its HOPE products in Washington, D.C. through a partnership with Alternative Solutions.
The HOPE products consist of two pharmaceutical-grade proprietary medicinal cannabis formulations developed to target Autism Spectrum Disorder (ASD) as a disease indication.
HOPE is now available at the National Holistic Healing Centre, a medicinal cannabis dispensary whose team assists patients in treating their symptoms through ailment-strain alignment.
This distribution will see Zelira’s HOPE range of products be accessible to patients registered across all states in the U.S., as they can legally purchase medical cannabis products at an approved dispensary in Washington, D.C.
“The successful launch of HOPE in Washington, D.C. is a huge step forward in Zelira’s strategic focus on expanding access to HOPE throughout the U.S.,” said Zelira Therapeutics Managing Director, Dr Oludare Odumosu.
“We look forward to partnering with Alternative Solutions to support the growth of our product in these new markets.”
As COVID restrictions gradually relax, Zelira says it remains focused on further expanding the distribution of HOPE through licensing agreements in each approved market across the U.S.
Zelira Therapeutics shares are trading steady at 5.3 cents at 10:00 am AEST.
